Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.73 |
| ▸ | CCR1 | P32246 | 2/20 | 0.73 |
| ▸ | PYGL | P06737 | 2/20 | 0.57 |
| ▸ | PYGM | P11217 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CCR4 | P51679 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126595 | 0.87 | CCR2 (0.55) | CCR2CCR1PYGLPYGMCYP1A2 | |
| SCHEMBL7118434 | 0.86 | PYGL (0.61) | CCR2CCR1PYGLPYGMCYP1A2 | |
| SCHEMBL7127256 | 0.86 | CCR2 (0.61) | CCR2CCR1PYGLPYGMCYP1A2 | |
| SCHEMBL7126634 | 0.86 | CCR1 (0.60) | CCR2CCR1PYGLCYP1A2CYP2C9 | |
| SCHEMBL3148243 | 0.85 | CCR2 (0.70) | CCR2CCR1CCR5 | |
| SCHEMBL7128331 | 0.83 | KDM4E (0.57) | CCR2CCR1PYGLPYGM | |
| SCHEMBL3144199 | 0.80 | CCR2 (0.68) | CCR2CCR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7125502 | 0.79 | PYGM (0.79) | PYGLPYGM | |
| SCHEMBL12200779 | 0.77 | CCR2 (0.73) | CCR2CCR1 | |
| SCHEMBL5117217 | 0.77 | CCR2 (0.59) | CCR2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | CCR2 4647/4885CCR1 4416/4885PYGL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.